Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Check Point Software Technologies Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Check Point Software Technologies Ltd trades at $129.5 (market cap $13.18B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.2× Check Point Software Technologies Ltd's market cap, and Check Point Software Technologies Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CHKP | |
|---|---|---|
Market Cap | $29.60B | $13.18B |
Sector | Health | Technology |
52-Week High | $491.22 | $206.91 |
52-Week Low | $205.48 | $112.47 |
Enterprise Value | $27.56B | $12.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
CHKP trades at $129.29, down 1.41% today, with a bearish technical signal as it hovers near support at $128. The stock shows strong fundamentals with a P/E of 13.24, net income margin of 37.93%, and consistent earnings beats in recent quarters. Recent news highlights AI security growth potential and insider selling activity.
The outlook is mixed: valuation appears attractive with a consensus price target of $146.92, but near-term risks include competitive pressures and margin declines. Upside depends on AI-driven revenue acceleration in 2027, while downside is capped by solid cash flow and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
